Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Advances deployment of mRNA technology across vaccines and therapeutics development
The facility is expected to be completed in 2024
Subscribe To Our Newsletter & Stay Updated
